P28482 (MK01_HUMAN) Homo sapiens (Human)
Mitogen-activated protein kinase 1 UniProtKBProtein AtlasInterProSTRINGInteractive Modelling
Available Structures
155 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Phosphorylated ERK2 in complex with ORF45 |
Heteromer F5HDE4; | 100 | 1×08G; 3×GOL; | |||
| ERK2 covalently bound to SynthRevD-12-opt artificial peptide |
Heteromer | 100.0 | 1×ANP; 2×GOL; | |||
| Heterodimeric structure of ERK2 and RSK1 |
Heteromer Q15418; | 100.0 | 2×ANP; 3×SO4; 2×NA; | |||
| Crystal structure of human ERK2 complexed with a MAPK docking peptide |
Heteromer P36507; | 98.86 | 1×ANP; | |||
| Phospho-ERK2 bound to bivalent inhibitor SBP3 |
Heteromer Q15418; | 100 | 5×GOL; 1×FRZ; 1×AKS; | |||
| Crystal structure of human ERK2 complexed with a MAPK docking peptide |
Heteromer Q9BUB5; | 100 | 1×ANP; | |||
| Structure of Non-Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain |
Heteromer Q9Z297; | 100.0 | 1×NA; | |||
| Phospho-ERK2 bound to bivalent inhibitor SBP2 |
Heteromer Q15418; | 100 | 3×GOL; 1×FRZ; 1×90A; | |||
| Crystal structure of human ERK2 complexed with a MAPK docking peptide |
Heteromer Q15418; | 99.42 | 1×ANP; | |||
| Crystal structure of human ERK2 complexed with a MAPK docking peptide |
Heteromer Q15418; | 99.41 | 1×ANP; | |||
| Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors. |
Heteromer P40763; | 100.0 | 1×5ID; | |||
| Structure of Dually Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain |
Heteromer Q15121; | 100 | ||||
| Structure of the complex between ERK2 phosphomimetic mutant and PEA-15 |
Heteromer Q15121; | 99.71 | 1×ADP; 4×SO4; | |||
| Cryo-EM structure of DHS-ERK2 complex with 1:1 stoichiometry refined in C1 symmetry |
Heteromer P49366; | 100.0 | ||||
| Crystal structure of HePTP in complex with a dually phosphorylated Erk2 peptide mimetic |
Heteromer P35236; | 75.0 | 3×CL; 1×GOL; | |||
| Crystal structure of HePTP in complex with a monophosphorylated Erk2 peptide |
Heteromer P35236; | 100 | 1×TAR; 1×GOL; | |||
| Complex of ERK2 with norathyriol | monomer | 100 | 1×NRA; 1×SO4; | |||
| Complex of ERK2 with caffeic acid | monomer | 100 | 1×DHC; 3×SO4; 1×PEG; 2×DMS; | |||
| Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #16 | monomer | 99.72 | 1×WAL; | |||
| Complex of ERK2 with catechol | monomer | 100 | 1×CAQ; 3×SO4; 2×NH4; | |||
| Crystal structure of ERK2 with an allosteric inhibitor 3 | monomer | 100 | 1×5ID; 1×EPE; 2×GOL; 1×B8Z; 1×SO4; | |||
| Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydr… | monomer | 100.0 | 3×SO4; 1×E86; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 2×PZO; | |||
| Crystal Structure of ERK2 in complex with compound 22 | monomer | 100.0 | 1×6QB; 2×EDO; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 2×SO4; 1×EQW; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 5×SO4; 1×ER8; | |||
| ERK2 covelently bound to RU77 cyclohexenone based inhibitor | monomer | 100.0 | 1×D7O; 3×GOL; 1×ANP; | |||
| Erk2 signalling protein | monomer | 100.0 | 5×SO4; 1×F0H; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 1×2AI; | |||
| ERK2 complexed with a N-H tetrahydroazaindazole | monomer | 100.0 | 1×4VB; | |||
| Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase | monomer | 100.0 | 1×4VF; 5×SO4; | |||
| Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase | monomer | 100.0 | 1×4VJ; 5×SO4; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 3×SO4; 1×ESQ; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100 | 2×SO4; 1×ERK; | |||
| Crystal structure of ERK2 with an allosteric inhibitor 2 | monomer | 100 | 1×5ID; 1×8DK; 3×GOL; 1×BTB; 1×SO4; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 3×SO4; 1×ERZ; | |||
| Crystal Structure of the ERK2 complexed with E63 | monomer | 100.0 | 1×E63; 4×SO4; 1×EDO; | |||
| Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase | monomer | 100.0 | 1×4VG; 4×SO4; | |||
| Crystal structure of human ERK2 complexed with a MAPK docking peptide | monomer | 100 | 1×ANP; | |||
| Crystal Structure of the ERK2 complexed with E71 | monomer | 100.0 | 1×E71; 5×SO4; 1×EDO; | |||
| Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrim… | monomer | 100.0 | 4×SO4; 1×Z48; | |||
| Crystal structure of ERK2 with an allosteric inhibitor | monomer | 100 | 1×5ID; 3×MLA; 2×SIN; 1×NA; 1×EPE; | |||
| The structure of ERK2 in complex with a small molecule inhibitor | monomer | 100 | 1×FRZ; | |||
| Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivative | monomer | 100 | 1×F29; | |||
| Structure of human ERK2 in complex with SCH772984 revealing a novel inhibitor-induced binding pocket | monomer | 100.0 | 8×EDO; 2×SO4; 1×38Z; | |||
| Crystal Structure of the ERK2 complexed with 5-Iodotubercidin | monomer | 100 | 1×5ID; 3×EDO; 4×SO4; 1×CL; | |||
| ERK2 covelently bound to RU76 cyclohexenone based inhibitor | monomer | 100 | 1×ANP; 1×E2A; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 2×SO4; 1×DMS; 1×F3Z; | |||
| ERK2 covelently bound to RU187 cyclohexenone based inhibitor | monomer | 100.0 | 1×ANP; 1×D5R; 1×GOL; | |||
| Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #8 | monomer | 100 | 1×W8U; | |||
| Phospho-ERK2 bound to AMP-PCP | monomer | 100 | 1×ACP; 6×GOL; 2×MG; | |||
| Crystal Structure of ERKs in complex with 5-chlorobenzo[d]oxazol-2-amine | monomer | 100.0 | 1×36R; 1×IMD; | |||
| Crystal Structure of the ERK2 complexed with EK9 | monomer | 100.0 | 1×EK9; 5×SO4; 1×EDO; | |||
| Crystal structure of human ERK2 mutant (G37C) | monomer | 99.71 | ||||
| Crystal Structure of the ERK2 complexed with E57 | monomer | 100.0 | 1×E57; 3×SO4; 1×EDO; | |||
| Crystal Structure of the ERK2 complexed with EK7 | monomer | 100.0 | 1×EK7; 3×SO4; 1×GOL; | |||
| Crystal structure of ERK2 in complex with an inhibitor 14K | monomer | 100.0 | 1×41B; | |||
| Crystal Structure of ERK2 in complex with (S)-2-((9H-purin-6-yl)amino)-3-phenylpropan-1-ol | monomer | 100.0 | 1×36Q; | |||
| Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine | monomer | 100.0 | 1×EMU; 1×IMD; | |||
| phosphorylated ERK2 with AMP-PNP | monomer | 100 | 1×ANP; 2×MG; | |||
| Crystal Structure of ERK2 in complex with 5H-pyrrolo[2,3-b]pyrazine | monomer | 100.0 | 1×36N; 1×IMD; | |||
| Structure of ERK2 in complex with VTX-11e, 4-{2-[(2-CHLORO-4-FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-… | monomer | 100 | 22×EDO; 5×SO4; 2×CL; 1×390; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 7×HVK; | |||
| Erk2 signalling protein | monomer | 100.0 | 7×SO4; 2×DMS; 1×GOL; 1×F0E; | |||
| ERK2 covelently bound to RU75 cyclohexenone based inhibitor | monomer | 100 | 1×ANP; 1×GOL; 1×EAI; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 5×SO4; 1×DMS; 1×EVK; | |||
| Crystal Structure of the ERK2 complexed with E94 | monomer | 100.0 | 1×E94; 3×SO4; 3×EDO; 1×GOL; | |||
| ERK2 covelently bound to RU60 cyclohexenone based inhibitor | monomer | 100.0 | 1×AN2; 1×DC6; | |||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.71 | 3×SO4; 1×8XH; | |||
| Crystal Structure of the ERK2 complexed with EK2 | monomer | 100.0 | 1×EK2; 2×SO4; 1×EDO; | |||
| Crystal Structure of the ERK2 | monomer | 100.0 | 1×EK0; 2×SO4; | |||
| ERK2 covalently bound to RU67 cyclohexenone based inhibitor | monomer | 100.0 | 1×AN2; 1×D2I; | |||
| Crystal Structure of the ERK2 complexed with EK3 | monomer | 100.0 | 1×EK3; 8×EDO; 2×GOL; | |||
| ERK2 complexed with 2-pyridiyl tetrahydroazaindazole | monomer | 100.0 | 1×NI; 1×4V9; | |||
| phosphorylated ERK2 with GDC-0994 | monomer | 100 | 1×6QB; | |||
| ERK2 complexed with N-benzylpyridone tetrahydroazaindazole | monomer | 100.0 | 1×4V8; 1×NI; | |||
| ERK2 covelently bound to RU68 cyclohexenone based inhibitor | monomer | 100.0 | 1×AN2; 1×EI0; | |||
| Specific covalent inhibitor of ERK2 | monomer | 100.0 | 2×SO4; 3×EDO; 1×DMS; 1×N8L; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 4×SO4; 2×HV2; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 2×HVB; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 4×SO4; 2×HVQ; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 4×HRZ; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 5×SO4; 1×EU2; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 4×SO4; 1×ERW; | |||
| The structure of ERK2 in complex with dual inhibitor ASTX029 | monomer | 100 | 3×SO4; 1×DMS; 1×RYW; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 2×SO4; 2×EQT; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 6×SO4; 1×ESN; | |||
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi… | monomer | 100.0 | 4×SO4; 1×UOH; | |||
| Specific covalent inhibitor of ERK2 | monomer | 100.0 | 2×SO4; 1×NYX; | |||
| In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitor | monomer | 100.0 | 1×6TS; 2×SO4; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 2×SO4; 3×DMS; 1×EVQ; | |||
| Specific covalent inhibitor (5) of ERK2 | monomer | 100.0 | 1×SO4; 1×EDO; 1×PEG; 1×N8U; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 1×HVE; | |||
| A Clickable Covalent ERK 1/2 Inhibitor | monomer | 100 | 4×SO4; 1×6TT; | |||
| WT ERK2 with compound 2507-8 | monomer | 99.71 | 1×SO4; 1×GOL; 1×KJ7; 1×KJ4; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 6×SO4; 1×EQZ; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 3×SO4; 1×ESK; | |||
| Crystal Structure of the ERK2 complexed with EK5 | monomer | 100.0 | 1×EK5; 2×SO4; 3×GOL; 5×EDO; | |||
| Crystal structure of ERK2 covalently bound to SM1-71 | monomer | 100 | 2×SO4; 1×6H3; 13×EDO; 1×CL; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 3×SO4; 2×HUH; | |||
| A multiconformer ligand model of EK6 bound to ERK2 | monomer | 100 | 3×SO4; 3×EDO; 1×EK6; | |||
| Crystal Structure of the ERK2 complexed with EK6 | monomer | 100 | 1×EK6; 3×SO4; 3×EDO; | |||
| Crystal Structure of the ERK2 complexed with E75 | monomer | 100.0 | 1×E75; 2×SO4; 1×EDO; | |||
| Crystal Structure of the ERK2 | monomer | 100.0 | 1×E28; 1×SO4; 4×EDO; | |||
| Crystal structure of human ERK2 mutant (Y36H) | monomer | 99.71 | 1×SO4; | |||
| phosphorylated ERK2 with SCH-CPD336 | monomer | 100.0 | 1×N0V; | |||
| The structure of ERK2 in complex with FR148083 | monomer | 100.0 | 1×1FM; | |||
| Specific covalent inhibitor(18) of ERK2 | monomer | 100.0 | 1×SO4; 1×EDO; 1×DMS; 1×PEG; 2×N96; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 2×HOW; | |||
| Specific covalent inhibitor(19) of ERK2 | monomer | 100 | 2×SO4; 2×EDO; 2×NX0; | |||
| Non-specific covalent inhibitor(17) of ERK2 | monomer | 100.0 | 1×SO4; 2×EDO; 3×N29; | |||
| Specific covalent inhibitor (8) of ERK2 | monomer | 100 | 2×SO4; 2×EDO; 1×N3X; | |||
| Specific covalent inhibitor(16) of ERK2 | monomer | 100.0 | 1×SO4; 2×EDO; 1×N4U; | |||
| Covalent and non-covalent inhibitor of ERK2 (two sites) | monomer | 100 | 1×SO4; 3×EDO; 1×DMS; 1×N83; 1×OZU; | |||
| Specific covalent inhibitor of ERK2 | monomer | 100 | 1×SO4; 2×EDO; 1×N3O; | |||
| Specific covalent inhibitor(14) of ERK2 | monomer | 100.0 | 2×SO4; 1×EDO; 1×NY0; 1×NYI; | |||
| Specific covalent inhibitor(10) of ERK2 | monomer | 100.0 | 1×SO4; 2×EDO; 2×PEG; 1×N4F; | |||
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi… | monomer | 100 | 3×SO4; 3×DMS; 1×EDO; 1×UOE; | |||
| Specific covalent inhibitor(15) of ERK2 | monomer | 100.0 | 1×SO4; 2×EDO; 1×N6U; | |||
| Specific covalent inhibitor(9) of ERK2 | monomer | 100.0 | 1×SO4; 2×EDO; 1×N5U; | |||
| ERK2 mini-fragment binding | monomer | 100.0 | 1×SO4; 2×IPH; | |||
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi… | monomer | 100 | 2×SO4; 2×DMS; 1×UNW; | |||
| electrophilic inhibitor (7) of ERK2 | monomer | 100.0 | 1×SO4; 1×PEG; 3×EDO; 1×N9F; | |||
| Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos… | monomer | 100.0 | 3×SO4; 1×ESW; | |||
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi… | monomer | 100.0 | 2×SO4; 1×UO5; | |||
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi… | monomer | 100.0 | 4×SO4; 1×DMS; 1×UMN; | |||
| Crystal Structure of the ERK2 complexed with EK4 | monomer | 100.0 | 1×EK4; 1×GOL; 1×SO4; 4×EDO; | |||
| Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-7-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyr… | monomer | 100.0 | 1×362; | |||
| Crystal Structure of ERK2 in complex with 7-(1-benzyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[… | monomer | 100.0 | 1×35W; | |||
| Human ERK2 in complex with an inhibitor | monomer | 99.7 | 1×SO4; 1×CQ8; | |||
| Human ERK2 in complex with an irreversible inhibitor | monomer | 99.71 | 1×SO4; 1×CQ3; | |||
| Specific covalent inhibitor (3) of ERK2 | monomer | 100.0 | 1×SO4; 1×EDO; 1×NXI; | |||
| Human ERK2 in complex with an irreversible inhibitor | monomer | 99.71 | 1×SO4; 1×CQ6; | |||
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi… | monomer | 100.0 | 1×SO4; 1×UOW; | |||
| Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Inhibitors of Erk2 | monomer | 100.0 | 1×2SH; | |||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.7 | 2×SO4; 1×8XK; | |||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.71 | 1×SO4; 1×8QB; | |||
| STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MA… | monomer | 98.5 | 1×SO4; 1×SB2; | |||
| Crystal Structure of ERK2 in complex with 7-(1-propyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[… | monomer | 100.0 | 1×35X; | |||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.71 | 1×SO4; 1×8XB; | |||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.71 | 2×SO4; 1×8XE; | |||
| Crystal Structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine | monomer | 100.0 | 1×36O; | |||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.71 | 1×SO4; 1×8XN; | |||
| Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine | monomer | 100.0 | 1×363; | |||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.71 | 2×SO4; 1×8X2; | |||
| Crystal structure of ERK2 G169D mutant | monomer | 99.7 | ||||
| Human Erk2 with an Erk1/2 inhibitor | monomer | 99.71 | 1×SO4; 1×8X5; | |||
| Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(… | monomer | 100 | 1×SO4; 1×82A; | |||
| Crystal structure of ERK2 in complex with N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrol… | monomer | 100 | 1×SO4; 1×33A; | |||
| Complex of ERK2 with 5,7-dihydroxychromone | monomer | 100 | 1×B7S; 1×SO4; 1×BEZ; | |||
| Specific covalent inhibitor (6) of ERK2 | monomer | 100.0 | 2×SO4; 1×EPE; 1×N6K; | |||
| HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364. | monomer | 99.7 | 1×LHZ; 2×SO4; 4×EDO; | |||
| Specific covalent inhibitor(12) of ERK2 | monomer | 100.0 | 1×SO4; 1×PEG; 1×NB3; | |||
| Inhibitor of ERK2 | monomer | 100.0 | 1×SO4; 1×KE8; | |||
| Crystal structure of ERK2 in complex with N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-ca… | monomer | 100.0 | 1×SO4; 1×19A; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4qtb.1.A | monomer | 0.89 | 1×38Z; | 87.90 | ||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 4qp3.1.A | monomer | 0.82 | 1×36Q; | 99.05 | ||